Novo Nordisk Makes Case For Alogliptin-Shadowed Victoza
This article was originally published in The Pink Sheet Daily
Executive Summary
Novo hopes the differing drug class and bigger Phase III trial will help diabetes drug get past heart-safety rules that tripped up the compound from Takeda.
You may also be interested in...
Saxagliptin Review Deadline Pushed Back; Approval Chances Still Look Good
FDA is extending the user fee goal date for action on Bristol-Myers Squibb/AstraZeneca's DPP-4 inhibitor antidiabetic Onglyza (saxagliptin) to July 30
Merck Bolsters Januvia Access With Outcomes-Based Discounts To CIGNA
Merck will provide CIGNA with price discounts on Januvia and Janumet that are tied to member outcomes - lower blood sugar and medication adherence - in a novel contract arrangement announced by CIGNA April 23
Saxagliptin Review Deadline Pushed Back; Approval Chances Still Look Good
FDA is extending the user fee goal date for action on Bristol-Myers Squibb/AstraZeneca's DPP-4 inhibitor antidiabetic Onglyza (saxagliptin) to July 30